TY - JOUR
T1 - Health-Related Quality of Life in Young Adult Survivors of Hematopoietic Cell Transplantation
AU - Rotz, Seth J.
AU - Yi, Jean C.
AU - Hamilton, Betty K.
AU - Wei, Wei
AU - Preussler, Jaime M.
AU - Cerny, Jan
AU - Deol, Abhinav
AU - Jim, Heather
AU - Khera, Nandita
AU - Hahn, Theresa
AU - Hashmi, Shahrukh K.
AU - Holtan, Shernan
AU - Jaglowski, Samantha M.
AU - Loren, Alison W.
AU - McGuirk, Joseph
AU - Reynolds, Jana
AU - Saber, Wael
AU - Savani, Bipin N.
AU - Stiff, Patrick
AU - Uberti, Joseph
AU - Wingard, John R.
AU - Wood, William A.
AU - Baker, K. Scott
AU - Majhail, Navneet S.
AU - Syrjala, Karen L.
N1 - Funding Information:
Conflict of interest statement: H.J.: consulting for Janssen Scientific Affairs and Merck and grant funding from Kite Pharma. J.R.W.: consulting for Celgene, Merck, Cidara, Takeda. S . K.H.: honoraria from Novartis, Mallinckrodt, Pfizer, and Janssen and consulting for Novartis, Kite, Juno, Takeda, and CRISPR. J.C.: consultant/advisory board member for Pfizer, Amgen, Jazz Pharmaceuticals; data safety and monitoring board member for Allovir; and stock ownership in Actinium Pharmaceuticals, bluebird bio/SeventyFour, Dynavax Pharma, Atyr Pharma, Gamida Cell, Miragen Therapeutics, Mustang Bio, Novavax, Ovid Therapeutics, Sorrento Therapeutics, TG Therapeutics, Vaxart, and Very. P.S.: consulting for CRISPR, Pfizer, and Morphosys and grant receipt from Gamida Cell, Amgen, Pfizer, Gilead, Incyte, Karyopharm, Cellectar, Bristol-Myers Squibb, Johnson and Johnson, Alovir, Atara, and Seattle Genetics. S.H.: research funding from Incyte and Vitrac Therapeutics; clinical trial adjudication for CSL Behring; and consulting for Generon and Ossium. The other authors have no conflicts of interest to report.
Funding Information:
Financial disclosure: Supported in part by a grant from PCORI (CD-12-11-4062 to the National Marrow Donor Program, K.S.B., N.S.M.) and grants from the National Cancer Institute ( R01 CA160684, to K.L.S.; R01 CA215134, to K.L.S., K.S.B., and N.S.M.; and U01 CA246659, to K.L.S. and K.S.B.) and the National Institutes of Health National Center for Advancing Translational Sciences ( 2KL2TR002547, to S.J.R.).The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health .
Funding Information:
Financial disclosure: Supported in part by a grant from PCORI (CD-12-11-4062 to the National Marrow Donor Program, K.S.B. N.S.M.) and grants from the National Cancer Institute (R01 CA160684, to K.L.S.; R01 CA215134, to K.L.S. K.S.B. and N.S.M.; and U01 CA246659, to K.L.S. and K.S.B.) and the National Institutes of Health National Center for Advancing Translational Sciences (2KL2TR002547, to S.J.R.).The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Conflict of interest statement: H.J.: consulting for Janssen Scientific Affairs and Merck and grant funding from Kite Pharma. J.R.W.: consulting for Celgene, Merck, Cidara, Takeda. S.K.H.: honoraria from Novartis, Mallinckrodt, Pfizer, and Janssen and consulting for Novartis, Kite, Juno, Takeda, and CRISPR. J.C.: consultant/advisory board member for Pfizer, Amgen, Jazz Pharmaceuticals; data safety and monitoring board member for Allovir; and stock ownership in Actinium Pharmaceuticals, bluebird bio/SeventyFour, Dynavax Pharma, Atyr Pharma, Gamida Cell, Miragen Therapeutics, Mustang Bio, Novavax, Ovid Therapeutics, Sorrento Therapeutics, TG Therapeutics, Vaxart, and Very. P.S.: consulting for CRISPR, Pfizer, and Morphosys and grant receipt from Gamida Cell, Amgen, Pfizer, Gilead, Incyte, Karyopharm, Cellectar, Bristol-Myers Squibb, Johnson and Johnson, Alovir, Atara, and Seattle Genetics. S.H.: research funding from Incyte and Vitrac Therapeutics; clinical trial adjudication for CSL Behring; and consulting for Generon and Ossium. The other authors have no conflicts of interest to report. Financial disclosure: See Acknowledgments on page 701.e6.
Publisher Copyright:
© 2022 The American Society for Transplantation and Cellular Therapy
PY - 2022/10
Y1 - 2022/10
N2 - Young adults (YA), age 18 to 39 years, are at a stage of life that may make them more vulnerable than older adults to impairments in health-related quality of life (HRQOL) during and after hematopoietic cell transplantation (HCT). Health self-efficacy (HSE), the belief that one can implement strategies to produce a desired health outcome, has been associated with health outcomes in oncology research. Little is known about HRQOL or HSE in YA HCT survivors compared with older HCT survivors. Given the age-specific psychosocial challenges facing YA HCT recipients and research on non-transplant YA cancer survivors, we hypothesized that YA survivors would have worse post-HCT HRQOL compared with older adults, and that among YA HCT survivors, higher levels of HSE would be associated with higher levels of HRQOL and lower levels of cancer-related distress. This was a cross-sectional secondary analysis of 2 combined baseline datasets from multicenter studies of HCT survivors approached for participation in clinical trials of survivorship interventions. Participants from 20 transplantation centers in the United States were at 1 to 10 years post-HCT and age ≥18 years at the time of study enrollment, had no evidence of disease relapse/progression or subsequent malignancies, and could read English adequately to consent for and complete assessments. Medical record and patient-reported data were obtained for demographics and HCT-related clinical factors and complications (eg, total body irradiation, chronic graft-versus-host disease [cGVHD]). Participants completed surveys on HRQOL, including the Short-Form [SF]-12, HSE, and Cancer and Treatment Distress (CTXD), which includes 6 subscales and reports an overall mean score. On the SF-12, both the Mental Component Score (MCS) and Physical Component Score (PCS) were calculated. Two cohorts were compared: YAs (age 18 to 39 years at transplantation) and older adults (age ≥40 years at transplantation). Multiple linear regression analyses identified factors associated with HSE, PCS, MCS, and CTXD in YAs. In this analysis of 979 survivors, compared with the older adults, the YA participants had lower median mental health scores (SF-12 MCS: 48.40 versus 50.23; P = .04) and higher cancer-related distress (CTXD:. 96 versus. 85; P = .04), but better physical health (SF-12 PCS: 48.99 versus 47.18; P = .049). Greater overall cancer-related distress was driven by higher levels of uncertainty, financial concern, and medical demand subscales for YAs compared with older adults. Young adults also had lower HSE (2.93 versus 3.08; P = .0004). In a multivariate model, HSE was strongly associated with age group (P = .0005) after adjusting for multiple other transplantation-related factors. Among YAs, HSE was associated with the SF-12 MCS and PCS and the CTXD, and HSE remained significant after adjusting for other transplantation-related factors. Overall, the YA HCT survivors had lower mental health, increased cancer-related distress, and lower levels of HSE compared with the older adults. Although the direction of these effects cannot be determined with these data, the strong association between HSE and HRQOL among YAs suggests that targeting interventions to improve HSE may have broad impact on health outcomes.
AB - Young adults (YA), age 18 to 39 years, are at a stage of life that may make them more vulnerable than older adults to impairments in health-related quality of life (HRQOL) during and after hematopoietic cell transplantation (HCT). Health self-efficacy (HSE), the belief that one can implement strategies to produce a desired health outcome, has been associated with health outcomes in oncology research. Little is known about HRQOL or HSE in YA HCT survivors compared with older HCT survivors. Given the age-specific psychosocial challenges facing YA HCT recipients and research on non-transplant YA cancer survivors, we hypothesized that YA survivors would have worse post-HCT HRQOL compared with older adults, and that among YA HCT survivors, higher levels of HSE would be associated with higher levels of HRQOL and lower levels of cancer-related distress. This was a cross-sectional secondary analysis of 2 combined baseline datasets from multicenter studies of HCT survivors approached for participation in clinical trials of survivorship interventions. Participants from 20 transplantation centers in the United States were at 1 to 10 years post-HCT and age ≥18 years at the time of study enrollment, had no evidence of disease relapse/progression or subsequent malignancies, and could read English adequately to consent for and complete assessments. Medical record and patient-reported data were obtained for demographics and HCT-related clinical factors and complications (eg, total body irradiation, chronic graft-versus-host disease [cGVHD]). Participants completed surveys on HRQOL, including the Short-Form [SF]-12, HSE, and Cancer and Treatment Distress (CTXD), which includes 6 subscales and reports an overall mean score. On the SF-12, both the Mental Component Score (MCS) and Physical Component Score (PCS) were calculated. Two cohorts were compared: YAs (age 18 to 39 years at transplantation) and older adults (age ≥40 years at transplantation). Multiple linear regression analyses identified factors associated with HSE, PCS, MCS, and CTXD in YAs. In this analysis of 979 survivors, compared with the older adults, the YA participants had lower median mental health scores (SF-12 MCS: 48.40 versus 50.23; P = .04) and higher cancer-related distress (CTXD:. 96 versus. 85; P = .04), but better physical health (SF-12 PCS: 48.99 versus 47.18; P = .049). Greater overall cancer-related distress was driven by higher levels of uncertainty, financial concern, and medical demand subscales for YAs compared with older adults. Young adults also had lower HSE (2.93 versus 3.08; P = .0004). In a multivariate model, HSE was strongly associated with age group (P = .0005) after adjusting for multiple other transplantation-related factors. Among YAs, HSE was associated with the SF-12 MCS and PCS and the CTXD, and HSE remained significant after adjusting for other transplantation-related factors. Overall, the YA HCT survivors had lower mental health, increased cancer-related distress, and lower levels of HSE compared with the older adults. Although the direction of these effects cannot be determined with these data, the strong association between HSE and HRQOL among YAs suggests that targeting interventions to improve HSE may have broad impact on health outcomes.
KW - HCT
KW - HRQOL
KW - HSE
KW - Self-efficacy
KW - Survivorship
KW - Young adult
UR - http://www.scopus.com/inward/record.url?scp=85136307766&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85136307766&partnerID=8YFLogxK
U2 - 10.1016/j.jtct.2022.07.018
DO - 10.1016/j.jtct.2022.07.018
M3 - Article
C2 - 35872304
AN - SCOPUS:85136307766
SN - 2666-6367
VL - 28
SP - 701.e1-701.e7
JO - Transplantation and Cellular Therapy
JF - Transplantation and Cellular Therapy
IS - 10
ER -